Home > Result Summaries: Compounds > fosamprenavir > Result Summary for APV10009

Result Summary for APV10009

Result Summary

Protocol ID:	APV10009
Clinical Study ID:	APV10009
Official Title:	A Phase I, Randomized Study to Assess the Effect of Efavirenz 600mg QD on Steady-State Plasma Total Amprenavir and Ritonavir PK Following Coadministration with GW433908 1395mg QD + Ritonavir 200mg QD or GW433908 1395mg QD + Ritonavir 300mg QD for 14 Days as Compared to GW433908 1395mg QD + Riton ...
Phase:	Phase 1
Study Indications or Diseases:	Infection, Human Immunodeficiency Virus
Generic Name:	fosamprenavir
Trade/Product Name:	lexiva;lexiva
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Abstract: an assessment of plasma amprenavir (apv) pharmacokinetics (pk) following administration of two gw433908 (908) and ritonavir (rtv) qd regimens in combination with efavirenz (efv) in healthy adult subjects (apv10009). M.B. WIRE1, S. L. PRESTON2 C. BALLOVV3 C. VV. HENDRIX4 Y. L0U1 P. PILIER02 D. S. STEIN1 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting Postponed from 22-25 Sep 2001 12/16/2001 Chicago, IL; USA Wire MB. Ballow C. Preston SL. Hendrix CW. Piliero PJ. Lou Y. Stein DS. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS. 18(6):897-907, 2004.